Finance

Novo Nordisk trims 2026 guidance on US pricing headwinds, exclusivity hits

Novo Nordisk guiding 2026 sales and operating profit down 5-13% at constant FX, citing US pricing headwinds and looming exclusivity expiries for Wegovy and Ozempic. The update signals a tougher near term despite ongoing Wegovy expansion and pipeline milestones.

📅 February 03, 2026
⏱️ 2 min read
Novo Nordisk trims 2026 guidance on US pricing headwinds, exclusivity hits

Key Takeaways

  • 2026 sales and operating profit expected to fall 5%-13% at constant FX due to US pricing headwinds.
  • Loss of exclusivity for Wegovy and Ozempic in China, Brazil and Canada in 2026 heightens revenue risk.
  • Wegovy oral launch in January 2026 and 7.2 mg dose rollout aim to lift volumes outside the US.
  • Competition from Lilly’s Mounjaro/Zepbound remains intense and pricing pressure persists in the US.
  • Analysts expect 2026 growth to slow to single digits; investors will watch Wegovy oral US uptake, 7.2 mg rollout and CagriSema milestones at the next earnings call.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Novo Nordisk A/SGlobal pharmaceutical company; maker of Wegovy and Ozempic
  • Eli Lilly and CompanyCompetitor; maker of Mounjaro and Zepbound
  • Wegovy (semaglutide)Weight-loss therapy from Novo Nordisk
  • Ozempic (semaglutide)GLP-1 therapy from Novo Nordisk
  • Mounjaro (tirzepatide)GLP-1 weight-loss drug from Eli Lilly
  • Zepbound (tirzepatide)Lilly weight-loss drug variant
  • CagriSemaNovo Nordisk experimental GLP-1/GIP dual agonist

MarketMoodz Analysis

The 2026 guidance implies meaningful near-term earnings risk for a large GLP-1 franchise that has benefited from rapid pricing growth in the US but now faces tightening pricing discipline and the loss of exclusivity in several markets. Even as Novo Nordisk expands Wegovy into more markets and leans on higher-dose offerings, the core US headwind presents a meaningful hurdle to top-line growth and margin expansion.

In historical context, the GLP-1 market has shifted from rapid adoption to a more value-conscious environment, with Lilly’s Mounjaro/Zepbound intensifying price and share competition. Ex-US growth and alternative formulations (oral Wegovy in the US and next-gen assets like CagriSema) remain critical to offset US weakness. The stock reaction—~14% drop in US ADRs after the news—reflects the crowd pricing in slower 2026 growth and the risk of further downgrades if guidance does not improve; investors will focus on the upcoming earnings call for milestones such as Wegovy oral US uptake and 7.2 mg rollout.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial